Cognoptix President & CEO, Susanne Wilke, PhD, MBA, to Present at Sachs 4th Annual Neuroscience Innovation Forum
News provided by
Share this article
Share this article
MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ Cognoptix, a leading medical device/diagnostics company dedicated to the early detection of Alzheimer s disease (AD), announced today that Dr. Susanne Wilke, the Company s President and Chief Executive Officer, will present a Spotlight Showcase of Cognoptix under the title Early-Stage Detection of Alzheimer s Disease – A Simple Eye Scan on Wednesday, April 28th at 12:10pm ET.
Millions of people are living with Alzheimer s and many millions more are at risk of developing the disease. Damaging forms of beta-amyloid begin building up in the brain 20 years before people begin to show signs of memory loss and confusion. At this time, amyloid PET brain scans are the only way to test for these damaging protein deposits while they are costly and time consuming. More
by Coating (Polymer-Based Coating and Polymer Free Coating), Application (Coronary Artery Disease and Peripheral Artery Disease), and End User (Hospitals, Ambulatory Surgical Centers, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027. According to the report, the global drug-eluting stents industry generated $6.38 billion in 2019, and is estimated to generate $8.77 billion by 2027, witnessing a CAGR of 8.7% from 2020 to 2027.
Prime determinants of growth
Surge in prevalence of cardiovascular disease, emergence of advanced drug-eluting stents, and increase in demand for minimally invasive surgical procedures drive the growth of the global drug-eluting stents market. However, strict government regulations for product approvals hinder the market growth. On the other hand, untapped potential in emerging countries presents new opportunities in the coming years.
Cholesterol testing
Immunization screening and administration not currently covered by Medicare Part B and D
Tobacco cessation services
Transition of care services
The legislation does not expand scope of practice, but brings Medicare rules in alignment with existing authorities already granted to pharmacists by many states and health care organizations through credentialing and privileging programs.
Similar legislation, H.R. 2759, was introduced in the U.S. House last week by Rep. G.K. Butterfield (D-NC) and Rep. David McKinley (R-WV).
Pharmacists have advanced education and training to deliver these patient care services, but unlike many states in the nation, Medicare does not recognize and reimburse them for such services. Pharmacists earn a Doctor of Pharmacy (PharmD) degree that includes six years to eight years of higher education to complete. Many pharmacists also complete one to two years of post-graduate residency training and become certified in a specialty by t
Share this article
Share this article
TAIPEI, April 27, 2021 /PRNewswire/ TCI Co., Ltd. (8436. TWO), the leading nutraceutical ODM company, announced on April 22nd that it is finally, after six months of review, recognized by the Science Based Targets Initiative (SBTi) as committed to aligning its actions to reduce greenhouse gas emissions with climate science and has become Asia s first biotechnology whose carbon emission reduction targets are validated by the SBTi.
TCI Co., Ltd. becomes Asia s first biotechnology company whose climate ambitions are validated by SBTi
TCI has long been paying attention to climate change and spared no effort to participate in international carbon reduction actions. In addition to being the first company in Taiwan to be invited to join RE100, this climate-ambitious biotech manufacturer has also been attending major international climate summits since 2018 to advocate the importance of sustainability, including the 2018 United Nations Climate
Share this article
Share this article
PITTSBURGH, April 27, 2021 /PRNewswire/ My daughter suffers from allergies but she hates taking allergy pills and using allergy drops, said an inventor, from New York, N.Y. I thought there could be a better allergy product to help her, so I invented the NYLAH WIPES. My design enables you to easily administer antihistamine and relieve itching and irritation caused by allergens.
The patent-pending invention provides effective relief for allergy sufferers. In doing so, it offers an alternative to taking antihistamine pills or allergy drops. As a result, it enables the user to remove pollen or other allergens from around the eyes and nose and it helps to soothe allergy/hay fever symptoms. The invention features a user-friendly design that is convenient and easy to use so it is ideal for adults and children. Additionally, it is producible in design variations.